Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial Academic Article Article uri icon

Overview

MeSH Major

  • Interferon-beta
  • Janus Kinase 2
  • Point Mutation
  • Polycythemia Vera
  • Polyethylene Glycols

abstract

  • Romiplostim was well tolerated, and increased and maintained platelet counts in splenectomised and non-splenectomised patients with ITP. Many patients were able to reduce or discontinue other ITP medications. Stimulation of platelet production by romiplostim may provide a new therapeutic option for patients with ITP.

authors

publication date

  • February 6, 2008

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0140-6736(08)60203-2

PubMed ID

  • 18242413

Additional Document Info

start page

  • 395

end page

  • 403

volume

  • 371

number

  • 9610